Researchers have identified a key mechanism driving neurological dysfunction in a mouse model of autism spectrum disorder (ASD), opening potential avenues for targeted therapeutic intervention. A study published in Nature details how overactivation of the translation initiation factor eIF4E leads to imbalanced protein synthesis, contributing to core ASD-like behaviors.
The research, conducted by scientists at Jinan University, centered on a mouse model created by prenatal exposure to valproic acid (VPA), a known ASD-associated teratogen. The team observed an exaggeration of global protein synthesis in the cerebral cortex of offspring mice exposed to VPA. Crucially, this increase wasn’t driven by changes in gene transcription, but rather by enhanced translation – the process of converting mRNA into proteins.
Integrative analysis of polyribosome-based translatome and proteome data revealed a remarkable upregulation of genes related to ribosomes and mitochondria in the VPA-exposed cortex, at both the translational and protein levels. Further investigation pinpointed eIF4E overactivation as the central driver of these aberrant changes. EIF4E is a critical regulator of mRNA translation, and its increased activity appears to favor the production of proteins involved in ribosomal function and mitochondrial activity.
The study demonstrated that pharmacological inhibition of eIF4E phosphorylation during the juvenile stage effectively mitigated ASD-like social deficits and stereotyped behavior in the VPA mice, with effects persisting into adulthood. This suggests a critical window for intervention and highlights the potential of targeting eIF4E signaling to address the underlying biological mechanisms of ASD.
The researchers employed a range of techniques to dissect the molecular pathways involved. They utilized polysome profiling to analyze mRNA translation rates, RNA sequencing to assess gene expression changes, and mass spectrometry to quantify protein levels. They also conducted behavioral tests, including a three-chamber social interaction test, open field tests, and self-grooming analysis, to assess ASD-like behaviors in the mice.
Further analysis revealed that eIF4E overactivation impacts synaptic function. Transmission electron microscopy showed alterations in mitochondrial morphology and synaptic structure in the VPA-exposed mice. The team also observed changes in the levels of synaptic proteins, including PSD95 and synaptophysin, suggesting impaired synaptic transmission.
The study also investigated the downstream signaling pathways activated by eIF4E. They found increased phosphorylation of several key proteins involved in translation, including 4E-BP1, 4E-BP2, mTOR, p70S6K, and RPS6. These findings suggest that eIF4E overactivation triggers a cascade of events that ultimately lead to increased protein synthesis.
To further validate their findings, the researchers conducted experiments in Neuro-2a cells, demonstrating that overexpression of eIF4E leads to increased puromycin incorporation – a marker of protein synthesis – and altered mitochondrial function. They also used a technique called FUNCAT to visualize protein synthesis in the cytoplasm and mitochondria, confirming that eIF4E overactivation promotes protein synthesis in both cellular compartments.
The implications of these findings extend beyond the VPA mouse model. Previous research, including a 2012 study published in PubMed, has linked dysregulation of eIF4E-dependent translational control to autism-related deficits. That earlier work showed that controlling eIF4E activity regulates the synthesis of neuroligins, proteins crucial for maintaining the balance between excitatory and inhibitory signals in the brain. Disruptions in this balance are thought to contribute to the neurological symptoms of ASD.
More recently, research highlighted in Cell Reports has demonstrated that an eIF4E transgenic mouse model of ASD exhibits behavioral inflexibility and impaired dopamine release in the striatum, linked to disrupted nicotinic acetylcholine receptor function. This suggests a broader role for eIF4E dysregulation in multiple brain regions and neurotransmitter systems affected in ASD.
The researchers treated VPA-exposed mice with eFT508, a pharmacological inhibitor of eIF4E phosphorylation, beginning at postnatal week 3. Behavioral testing at weeks 4-6 and 9 showed improvements in several ASD-like behaviors. This provides further evidence for the therapeutic potential of targeting eIF4E signaling.
While the study provides compelling evidence for the role of eIF4E overactivation in ASD pathogenesis, further research is needed to determine whether these findings translate to humans. However, the identification of eIF4E as a key therapeutic target represents a significant step forward in the development of novel treatments for this complex neurodevelopmental disorder. The study underscores the importance of understanding the intricate molecular mechanisms underlying ASD to develop effective interventions.